Covance Inc: (NYSE: CVD)

$77.42

1.11 (1.46%)

Volume 181,799

May 14 04:03 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		76.30 - 77.44
	
		52wk Low - High
		44.19 - 78.36
	
		Previous Close
		76.31
	
		Avg. Volume
		496,970
	
		Industry
		MEDICAL SERVICES
	
		Market Cap
		4.21 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.14
	
		PE (Forward)
		24.49
	
		Current Year Est.
		3.12
	
		Quarterly Earnings ESP 
		1.33%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		103 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            24.49
                        
                            PEG Ratio
                            1.91
                        
                            Current Year Est.
                            3.12
                        
                            Current Quarter Estimate
                            0.75
                        
                            Most Accurate Estimate
                            0.76
                        
                            Earnings ESP 
                            1.33%
                        
                            Next Earnings Report Date
                            07-24-2013
                        
                            EPS Last Year
                            2.85
                        
                            Expected Earnings Growth
                            12.83%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Covance Inc. is a leading contract research organization providing a wide range of product development services on a worldwide basis to the pharmaceutical, biotechnology and medical device industries.  The company also provide health economics and outcomes services for managed care organizations, hospitals and other health care providers and laboratory testing services to the chemical, agrochemical and food industries.   
Full CVD Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CVD Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.75	0.77	3.12	3.66
Number of Estimates	11	10	11	11
Low Estimate	0.72	0.74	3.01	3.34
High Estimate	0.78	0.80	3.16	NA
Year Ago EPS	0.65	0.72	2.70	3.12
EPS Growth	16.08%	7.50%	15.39%	17.42%

More CVD Estimates

Average Earnings Estimates for CVD

EPS Growth for CVD

Industry Analysis

Name	Symbol	Previous Close
COVANCE INC	CVD	76.31
ICON PLC	ICLR	33.01
IPC THE HOSPITL	IPCM	48.48
OMNICARE INC	OCR	45.32
PAREXEL INTL CP	PRXL	45.07
ADVISORY BOARD	ABCO	49.64
BG MEDICINE INC	BGMD	1.67
CATAMARAN CORP	CTRX	51.22
EXPRESS SCRIPTS	ESRX	61.94
HEALTHWAYS INC	HWAY	14.46

Sector:Medical>> Industry:MEDICAL SERVICES

COMPARE TICKER vs. Its Peers

Zacks Commentary

ABCO Posts Solid 4Q and FY2013 Earnings

May 13, 2013

Covance Beats Earnings, Rev, Ups View

May 06, 2013

Covance Augments Singapore Facility

Apr 16, 2013

Reiterate Healthways at Neutral

Mar 12, 2013

HWAY and Wellmont Collaborate

Feb 25, 2013

Omnicare Tops Est., Higher Profit

Feb 20, 2013

ESRX Reports In-Line 4Q Earnings

Feb 19, 2013

Mixed 4Q for Charles River

Feb 14, 2013

More CVD Zacks Commentary

Financials

EPS TTM	2.85
Sales	2,366
Net Income	107
Price/Earnings	26.77
Price/Book	3.13
Price/Cash Flow	15.49
Price/Sales	1.73

More CVD Financials

News

Blackrock(R) Announces May Monthly Cash Distributions for the iShares(R) Funds - Marketwire Canada

May 14, 2013

Blackrock(R) Announces May Monthly Cash Distributions for theiShares(R) Funds - Marketwire

May 14, 2013

Covance (CVD) Trading Near $77.58 Resistance Level - Freshbrewedmedia

May 13, 2013

Covance To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - Pr Newswire

May 13, 2013

Covance In Retrospect: Shares Down 0.6% Since Downgraded One Week Ago (CVD) - Financial News Network Online - News Corner

May 10, 2013

Shares of Bruker Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (BRKR, PKI, PRXL, TMO, CVD) - Financial News Network Online - News Corner

May 10, 2013

Quintiles IPO Cleans Up As New Issues Multiply - Investors Business Daily

May 9, 2013

Shares of Bruker Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (BRKR, PKI, PRXL, TMO, CVD) - Financial News Network Online - News Corner

May 9, 2013

See All News Stories on CVD

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.00
# of recs in ABR	12
Average Target Price	71.00
Industry Rank by ABR	103 out of 265
Rank in Industry	1 out of 15

More CVD Broker Recommendations

Day Low - High	76.30 - 77.44
52wk Low - High	44.19 - 78.36
Previous Close	76.31
Avg. Volume	496,970
Industry	MEDICAL SERVICES
Market Cap	4.21 B
Div - Yield	0.00 - 0.00
Beta	1.14
PE (Forward)	24.49
Current Year Est.	3.12
Quarterly Earnings ESP	1.33%

PE (Forward)	24.49
PEG Ratio	1.91
Current Year Est.	3.12
Current Quarter Estimate	0.75
Most Accurate Estimate	0.76
Earnings ESP	1.33%
Next Earnings Report Date	07-24-2013
EPS Last Year	2.85
Expected Earnings Growth	12.83%

Username: Password:

Remember me [?]

Covance Inc: (NYSE: CVD)

$77.42

1.11 (1.46%)

Volume 181,799

May 14 04:03 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MEDICAL SERVICES

Zacks Commentary

Financials

News

Broker Recommendations